TAM May 2018 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
May 2018, Volume 26, Issue 1
- CME Credit Available: 10.75 AMA PRA Category 1 Credits™
- Release Date: May 3, 2018
- Expiration Date: May 3, 2019
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
On completion of this activity, the learner will be able to describe the important new data presented at the 2018 Conference on Retroviruses and Opportunistic Infections and the potential clinical implications for patients in the areas of:
- Epidemiology of HIV and HIV prevention efforts
- Basic science understanding of HIV
- Complications of HIV disease
- Viral hepatitis
- Antiretroviral therapy for HIV prevention and management
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV infection.
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and HCV infections.
This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 10.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from May 3, 2018, to May 3, 2019. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, authors, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing medical education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Dr Buchbinder has participated in research trials that received provision of medicines from Gilead Sciences, Inc.(Updated 4/26/18)
Dr Liu has participated in research trials that received provision of medicines from Gilead Sciences, Inc. (Updated 03/29/18)
Dr Stevenson has no relevant financial affiliations to disclose. (Updated 04/09/18)
Dr Currier has received grant support awarded to her institution from Theratechnologies. (Updated 04/04/18)
Dr Havlir has no relevant financial affiliations to disclose. (Updated 04/16/18)
Dr Luetkemeyer has received grant support awarded to her institution from AbbVie, Gilead Sciences, Inc, Merck and Proteus, and had travel paid for by Merck. (Updated 04/24/18)
Dr Wyles has received grant support awarded to his institution from AbbVie, Gilead Sciences, Inc, Merck, and Tacere, and has served as a consultant or advisor to AbbVie, Gilead Sciences, Inc, and Merck. (Updated 04/16/18)
Dr Tieu has received grant support awarded to her institution from Merck. (Updated 4/9/2018)
Dr Wilkin has served as a consultant to and received grant support awarded to his institution from GlaxoSmithKline/ViiV Healthcare, and his spouse owns stock in Johnson & Johnson. (Updated 04/14/18)
Dr Jones has no relevant financial affiliations to disclose. (Updated 04/14/18)
Dr Taylor has no relevant financial affiliations to disclose. (Updated 04/09/18)
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 05/01/18)
The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Independent educational grants for the 2018 Improving the Management of HIV Disease® CME program:
Gilead Sciences, Inc
Independent educational grants for the 2018 Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes CME program:
Gilead Sciences, Inc
Additional Support Provided by
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.
If you have any questions about this activity, please contact the IAS–USA:
Mail: 425 California St, Ste 1450, San Francisco, CA 94104-2120
Phone: (415) 544-9400
Fax: (415) 544-9401
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.